MITM IPA-Mysuru Local Branch, JSS Pharmacy College, Mysuru & others note importance of Healthy Women –Healthy Society: Our ...

SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025 ...

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome: Tokyo, Japan Monday, October 20, 2025, 18:00 Hrs [IST] Renalys Pharma, ...

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Tolremo therapeutics completes first in human dose escalation for TT125-802 and presents solid tumour monotherapy results at ESMO 2025: Basel Monday, October 20, 2025, 15:30 Hrs [ ...

Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC: Ingelheim, Germany Monday, Oc ...

Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen ...

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...

Our Bureau, Bengaluru Monday, October 20, 2025, 15:20 Hrs [IST] Biocon Biologics, a global leader in biosimilars and the world ...

Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment: Indianapolis Monday, October 20, 2025, 12:00 Hrs [IST] Eli Lilly and ...

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event ...

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...